BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 14976565)

  • 1. Comparison of rabeprazole-based four- and seven-day triple therapy and omeprazole-based seven-day triple therapy for Helicobacter pylori infection in patients with peptic ulcer.
    Yang KC; Wang GM; Chen JH; Chen TJ; Lee SC
    J Formos Med Assoc; 2003 Dec; 102(12):857-62. PubMed ID: 14976565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-day triple therapy with rabeprazole, amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease--A pilot study.
    Lüth S; Teyssen S; Kölbel CB; Singer MV
    Z Gastroenterol; 2001 Apr; 39(4):279-81, 284-5. PubMed ID: 11367976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial.
    Calvet X; Ducons J; Bujanda L; Bory F; Montserrat A; Gisbert JP;
    Am J Gastroenterol; 2005 Aug; 100(8):1696-701. PubMed ID: 16086704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A prospective study on rabeprazole-based triple therapy for Helicobacter pylori eradication in patients with peptic ulcer].
    Choi BK; Yang SY; Park ET; Jang YS; Lee YJ; Lee SH; Seol SY; Chung JM
    Korean J Gastroenterol; 2003 Aug; 42(2):102-7. PubMed ID: 14532713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin.
    Isomoto H; Furusu H; Ohnita K; Wen CY; Inoue K; Kohno S
    World J Gastroenterol; 2005 Mar; 11(11):1629-33. PubMed ID: 15786539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole.
    Miwa H; Yamada T; Sato K; Ohta K; Ohkura R; Murai T; Nagahara A; Takei Y; Ogihara T; Sato N
    Dig Dis Sci; 2000 Jan; 45(1):77-82. PubMed ID: 10695617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study.
    Gambaro C; Bilardi C; Dulbecco P; Iiritano E; Zentilin P; Mansia C; Usai P; Vigneri S; Savarino V
    Dig Liver Dis; 2003 Nov; 35(11):763-7. PubMed ID: 14674665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease.
    Hawkey CJ; Atherton JC; Treichel HC; Thjodleifsson B; Ravic M
    Aliment Pharmacol Ther; 2003 Apr; 17(8):1065-74. PubMed ID: 12694089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients.
    Park HG; Jung MK; Jung JT; Kwon JG; Kim EY; Seo HE; Lee JH; Yang CH; Kim ES; Cho KB; Park KS; Lee SH; Kim KO; Jeon SW
    Aliment Pharmacol Ther; 2012 Jan; 35(1):56-65. PubMed ID: 22066530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seven-day therapy for Helicobacter pylori in the United States.
    Vakil N; Lanza F; Schwartz H; Barth J
    Aliment Pharmacol Ther; 2004 Jul; 20(1):99-107. PubMed ID: 15225176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low and high doses of rabeprazole vs. omeprazole for cure of Helicobacter pylori infection.
    Kositchaiwat C; Ovartlarnporn B; Kachintorn U; Atisook K
    Aliment Pharmacol Ther; 2003 Nov; 18(10):1017-21. PubMed ID: 14616168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration.
    Stack WA; Knifton A; Thirlwell D; Cockayne A; Jenkins D; Hawkey CJ; Atherton JC
    Am J Gastroenterol; 1998 Oct; 93(10):1909-13. PubMed ID: 9772054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection.
    Sharara AI; Chaar HF; Racoubian E; Moukhachen O; Barada KA; Mourad FH; Araj GF
    Helicobacter; 2004 Jun; 9(3):255-61. PubMed ID: 15165262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study.
    De Francesco V; Zullo A; Hassan C; Della Valle N; Pietrini L; Minenna MF; Winn S; Monno R; Stoppino V; Morini S; Panella C; Ierardi E
    Dig Liver Dis; 2004 May; 36(5):322-6. PubMed ID: 15191200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study.
    Andreev DN; Maev IV; Dicheva DT; Samsonov AA; Partzvania-Vinogradova EV
    Ter Arkh; 2018 Aug; 90(8):27-32. PubMed ID: 30701936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of 1-week and 2-week triple therapy with omeprazole, amoxicillin, and clarithromycin in peptic ulcer patients with Helicobacter pylori infection: results of a randomized controlled trial.
    Kiyota K; Habu Y; Sugano Y; Inokuchi H; Mizuno S; Kimoto K; Kawai K
    J Gastroenterol; 1999; 34 Suppl 11():76-9. PubMed ID: 10616771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection.
    Wong BC; Wong WM; Yee YK; Hung WK; Yip AW; Szeto ML; Li KF; Lau P; Fung FM; Tong TS; Lai KC; Hu WH; Yuen MF; Hui CK; Lam SK
    Aliment Pharmacol Ther; 2001 Dec; 15(12):1959-65. PubMed ID: 11736727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study.
    Zullo A; Gatta L; De Francesco V; Hassan C; Ricci C; Bernabucci V; Cavina M; Ierardi E; Morini S; Vaira D
    Aliment Pharmacol Ther; 2005 Jun; 21(12):1419-24. PubMed ID: 15948808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole.
    Miwa H; Ohkura R; Murai T; Sato K; Nagahara A; Hirai S; Watanabe S; Sato N
    Aliment Pharmacol Ther; 1999 Jun; 13(6):741-6. PubMed ID: 10383502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy.
    Wang HH; Chou JW; Liao KF; Lin ZY; Lai HC; Hsu CH; Chen CB
    World J Gastroenterol; 2005 Mar; 11(11):1680-4. PubMed ID: 15786549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.